1. Home
  2. TRS vs REPL Comparison

TRS vs REPL Comparison

Compare TRS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriMas Corporation

TRS

TriMas Corporation

SELL

Current Price

$38.44

Market Cap

1.4B

Sector

Industrials

ML Signal

SELL

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$13.04

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRS
REPL
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
TRS
REPL
Price
$38.44
$13.04
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
★ $45.00
$19.50
AVG Volume (30 Days)
237.9K
★ 2.1M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 0.42%
N/A
EPS Growth
★ 400.00
N/A
EPS
★ 21.96
N/A
Revenue
★ $645,720,000.00
N/A
Revenue This Year
$4.95
N/A
Revenue Next Year
$2.79
$497.81
P/E Ratio
$1.74
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$30.43
$1.50
52 Week High
$45.43
$16.33

Technical Indicators

Market Signals
Indicator
TRS
REPL
Relative Strength Index (RSI) 45.93 46.94
Support Level $38.15 $12.40
Resistance Level $39.91 $13.64
Average True Range (ATR) 0.84 0.70
MACD -0.01 0.02
Stochastic Oscillator 27.71 62.03

Price Performance

Historical Comparison
TRS
REPL

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: